Cover Image
市場調查報告書

尼古丁中毒症:開發中產品分析

Nicotine Addiction - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 245978
出版日期 內容資訊 英文 64 Pages
訂單完成後即時交付
價格
Back to Top
尼古丁中毒症:開發中產品分析 Nicotine Addiction - Pipeline Review, H2 2016
出版日期: 2016年08月17日 內容資訊: 英文 64 Pages
簡介

尼古丁中毒是由於尼古丁藥物成癮所引起的香煙產品成癮症。致病要素有年齡、憂鬱症傾向、思覺失調症、PTSD、酒精成癮等,停止攝取尼古丁時會出現手顫抖、發汗、神經過敏、心律上升等禁斷症狀。可用尼古丁替代療法進行治療。

本報告提供尼古丁中毒症治療藥的開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

  • 調查範圍

尼古丁中毒症概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

尼古丁中毒症:企業開發中的治療藥

尼古丁中毒症:大學/機關研究中的治療藥

尼古丁中毒症:開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

尼古丁中毒症:企業開發中的產品

尼古丁中毒症:大學/機關研究中的產品

尼古丁中毒症的治療藥開發企業

  • Addex Therapeutics Ltd
  • Astraea Therapeutics, LLC
  • Cerecor Inc.
  • Embera NeuroTherapeutics, Inc.
  • Hager Biosciences, LLC
  • Heptares Therapeutics Limited
  • Omeros Corporation
  • RTI International

尼古丁中毒症:治療藥的評估

  • 單劑產品
  • 組合產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

尼古丁中毒症:最近的開發平台趨勢

尼古丁中毒症:暫停中的計劃

尼古丁中毒症:中止開發的產品

尼古丁中毒症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8366IDB

Summary

Global Markets Direct's, 'Nicotine Addiction - Pipeline Review, H2 2016', provides an overview of the Nicotine Addiction pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Nicotine Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Nicotine Addiction and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nicotine Addiction
  • The report reviews pipeline therapeutics for Nicotine Addiction by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved Nicotine Addiction therapeutics and enlists all their major and minor projects
  • The report assesses Nicotine Addiction therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for Nicotine Addiction

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for Nicotine Addiction
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nicotine Addiction pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nicotine Addiction Overview
  • Therapeutics Development
    • Pipeline Products for Nicotine Addiction - Overview
    • Pipeline Products for Nicotine Addiction - Comparative Analysis
  • Nicotine Addiction - Therapeutics under Development by Companies
  • Nicotine Addiction - Therapeutics under Investigation by Universities/Institutes
  • Nicotine Addiction - Pipeline Products Glance
    • Clinical Stage Products
    • Early Stage Products
  • Nicotine Addiction - Products under Development by Companies
  • Nicotine Addiction - Products under Investigation by Universities/Institutes
  • Nicotine Addiction - Companies Involved in Therapeutics Development
    • Addex Therapeutics Ltd
    • Astraea Therapeutics, LLC
    • Cerecor Inc.
    • Chronos Therapeutics Limited
    • Embera NeuroTherapeutics, Inc.
    • Hager Biosciences, LLC
    • Heptares Therapeutics Limited
    • Omeros Corporation
  • Nicotine Addiction - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Combination Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • (metyrapone + oxazepam) - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ADX-71441 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • AT-1001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CERC-501 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • EORA-101 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-405 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule for Psychiatric Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize Alpha-4 Beta-2 Nicotinic Acetylcholine Receptor for CNS Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Antagonize CRF-R1 and OREXIN-1 for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine Transporter for CNS and Metabolic Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • URB-694 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Nicotine Addiction - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nicotine Addiction - Dormant Projects
  • Nicotine Addiction - Discontinued Products
  • Nicotine Addiction - Product Development Milestones
    • Featured News & Press Releases
      • Dec 11, 2015: Publication Reports Human Brain Penetration and Target Engagement of Cerecor's Oral Kappa Opioid Receptor Antagonist, CERC-501
      • Jul 10, 2014: Addex ADX71441 Positive Results in Preclinical Model of Nicotine Addiction
      • Mar 19, 2013: Omeros Elucidates Mechanism Of PDE7 Inhibitors In Addiction
      • Feb 16, 2012: Molecular Express announces award of STTR Phase I funding from the National Institutes of Health to develop a liposomal nicotine vaccine
      • May 05, 2011: Omeros Announces Expansion Of Potential Indications For PDE7 Inhibitors
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Nicotine Addiction, H2 2016
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Nicotine Addiction - Pipeline by Addex Therapeutics Ltd, H2 2016
  • Nicotine Addiction - Pipeline by Astraea Therapeutics, LLC, H2 2016
  • Nicotine Addiction - Pipeline by Cerecor Inc., H2 2016
  • Nicotine Addiction - Pipeline by Chronos Therapeutics Limited, H2 2016
  • Nicotine Addiction - Pipeline by Embera NeuroTherapeutics, Inc., H2 2016
  • Nicotine Addiction - Pipeline by Hager Biosciences, LLC, H2 2016
  • Nicotine Addiction - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Nicotine Addiction - Pipeline by Omeros Corporation, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Assessment by Combination Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Nicotine Addiction - Dormant Projects, H2 2016
  • Nicotine Addiction - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Nicotine Addiction, H2 2016
  • Number of Products under Development for Nicotine Addiction - Comparative Analysis, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Top 10 Targets, H2 2016
  • Number of Products by Stage and Top 10 Targets, H2 2016
  • Number of Products by Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top